Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rogdi atypical leucine zipper is a highly conserved, monomeric leucine zipper-like protein, present in metazoan organisms, encoded by the ROGDI gene on human chromosome 16[1][2][3][4][5]. Its structure comprises a unique curved architecture with a core four-helix bundle and a β-sheet domain, forming a leucine zipper-like but functionally and structurally distinct motif from classical coiled-coil ZIP proteins[1]. It is expressed at highest levels in the brain and spinal cord and is implicated in the development of the nervous system and teeth[5][3]. Mutations in ROGDI cause Kohlschutter-Tonz syndrome, a rare autosomal recessive disorder featuring epilepsy, spasticity, global developmental delay, and amelogenesis imperfecta (defective tooth enamel)[1][2][3][5]. Rogdi interacts with other neuronal proteins, including DISC1, suggesting a role for protein scaffolding in neurogenesis[1]. Despite its structural characterization, there is no evidence that Rogdi is a conventional therapeutic target such as a receptor, enzyme, ion channel, or transporter, and no drugs are currently known to act on Rogdi[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rogdi atypical leucine zipper (ROGDI).